Long-term protease inhibitor-containing therapy results in limited improvement in T cell function but not restoration of interleukin-12 production in pediatric patients with AIDS

J Infect Dis. 2001 Jul 15;184(2):201-5. doi: 10.1086/322006. Epub 2001 Jun 8.

Abstract

This study investigated whether immune restoration occurred in 26 human immunodeficiency virus (HIV) type 1-infected children treated first with indinavir for 16 weeks and then with combination antiretroviral therapy for >2 years. Compared with baseline, a significant, although modest, decrease in virus loads (maximum median, -0.86 log(10)) and increase in the number of CD4(+) lymphocytes, especially naive cells, were observed at several time points after 2 years. A maximum of 7% of treated children achieved undetectable viremia. There was a marked increase in the proliferative response and skin reactivity to recall antigens. However, responses to an HIV antigen remained depressed, and the production of interleukin-12 remained unchanged and abnormally low. The magnitude of virus suppression did not correlate with these measures of functional immune reconstitution. These findings suggest that long-term nonsuppressive antiretroviral therapy can induce limited improvement in immune function in pediatric AIDS patients and that the effect of suppressive treatments should be investigated.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • Clinical Trial, Phase II

MeSH terms

  • Acquired Immunodeficiency Syndrome / drug therapy*
  • Acquired Immunodeficiency Syndrome / immunology
  • Adolescent
  • Anti-HIV Agents / therapeutic use*
  • CD4 Lymphocyte Count
  • Child
  • Child, Preschool
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • HIV Antigens / blood
  • HIV Protease Inhibitors / therapeutic use*
  • Humans
  • Indinavir / therapeutic use
  • Interleukin-12 / biosynthesis*
  • Lamivudine / therapeutic use
  • Male
  • Phytohemagglutinins / blood
  • T-Lymphocytes / drug effects*
  • T-Lymphocytes / immunology*
  • Time Factors
  • Treatment Outcome
  • Viral Load
  • Zidovudine / therapeutic use

Substances

  • Anti-HIV Agents
  • HIV Antigens
  • HIV Protease Inhibitors
  • Phytohemagglutinins
  • Interleukin-12
  • Lamivudine
  • Zidovudine
  • Indinavir